Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
The company is planning to offer Galaxy Store developers an 80 / 20 revenue share on games beginning May 15th. Currently, it’s 70 / 30. According to Seline Sangsook Han, Samsung EVP of Mobile Service ...
Samsung SDI, South Korea’s second-largest battery manufacturer, has announced plans to raise 2 trillion won ($1.37 billion) ...
WRIC Richmond on MSN1d
Samsung halts investment, announces layoffs in Mexico due to tariffs uncertaintySamsung currently operates two plants in Mexico, one in Tijuana and one in the city of Querétaro, where the company was ...
Khaleej Times on MSN6d
Samsung confirms One UI 7 stable release for April: Here’s what to expectThis news marks the end of a long wait for many Samsung users, particularly those with devices from the Galaxy S23 and S24 ...
Pharmaceutical Technology on MSN17d
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contractSamsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...
(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback